| Literature DB >> 18692574 |
Benxiu Ji1, Lauren C Case, Kai Liu, Zhaohui Shao, Xinhua Lee, Zhongshu Yang, Joy Wang, Tim Tian, Svetlana Shulga-Morskaya, Martin Scott, Zhigang He, Jane K Relton, Sha Mi.
Abstract
Oligodendrocyte-myelin glycoprotein (OMgp) is a myelin component that has been shown in vitro to inhibit neurite outgrowth by binding to the Nogo-66 receptor (NgR1)/Lingo-1/Taj (TROY)/p75 receptor complex to activate the RhoA pathway. To investigate the effects of OMgp on axon regeneration in vivo, OMgp(-/-) mice on a mixed 129/Sv/C57BL/6 (129BL6) or a C57BL/6 (BL6) genetic background were tested in two spinal cord injury (SCI) models - a severe complete transection or a milder dorsal hemisection. OMgp(-/-) mice on the mixed 129BL6 genetic background showed greater functional improvement compared to OMgp(+/+) littermates, with increased numbers of cholera toxin B-labeled ascending sensory axons and 5-HT(+) descending axons and less RhoA activation after spinal cord injury. Myelin isolated from OMgp(-/-) mice (129BL6) was significantly less inhibitory to neurite outgrowth than wild-type (wt) myelin in vitro. However, OMgp(-/-) mice on a BL/6 genetic background showed neither statistically significant functional recovery nor axonal sprouting following dorsal hemisection.Entities:
Mesh：
Substances：
Year: 2008 PMID： 18692574 PMCID： PMC2646371 DOI： 10.1016/j.mcn.2008.07.004
Source DB: PubMed Journal: Mol Cell Neurosci ISSN： 1044-7431 Impact factor: 4.314